SCHEMBL4757672

SCHEMBL4757672

CC(C)C1Cc2cc3cc(C(N)=O)sc3nc2CC1C

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HSP90AB1 P08238 1/20 0.36
DAPK3 O43293 2/20 0.35
CSNK1A1 P48729 2/20 0.35
LIMK1 P53667 2/20 0.35
ROCK1 Q13464 2/20 0.35
CLK4 Q9HAZ1 2/20 0.35
DYRK1B Q9Y463 2/20 0.35
TNK2 Q07912 1/20 0.35
KDR P35968 2/20 0.34
CHEK1 O14757 1/20 0.34
AURKA O14965 1/20 0.34
PRKD3 O94806 1/20 0.34
MAP4K4 O95819 1/20 0.34
PAK4 O96013 1/20 0.34
ABL1 P00519 1/20 0.34
RET P07949 1/20 0.34
PIM1 P11309 1/20 0.34
FGFR1 P11362 1/20 0.34
PRKACA P17612 1/20 0.34
FLT1 P17948 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4704935 0.82 HSP90AB1 (0.37) HSP90AB1DAPK3CSNK1A1LIMK1ROCK1
SCHEMBL4706426 0.76 PNMT (0.34) KDM4E
SCHEMBL4705577 0.72 RAB9A (0.38) HSP90AB1DAPK3CSNK1A1LIMK1ROCK1
SCHEMBL4702022 0.71 MAPT (0.40) HSP90AB1DAPK3CSNK1A1LIMK1ROCK1
SCHEMBL29926293 0.71 NPC1 (0.57) HSP90AB1DAPK3CSNK1A1LIMK1ROCK1
SCHEMBL13154846 0.70 MAPT (0.40) HSP90AB1DAPK3CSNK1A1LIMK1ROCK1
SCHEMBL22699072 0.63 NPC1 (0.44) KDM4ENPC1RAB9ASMN1; SMN2ALDH1A1
SCHEMBL5996076 0.61 ALDH1A1 (0.39) KDM4ENPC1RAB9ASMN1; SMN2ALDH1A1
SCHEMBL22699253 0.60 ALDH1A1 (0.39) KDM4ENPC1RAB9ASMN1; SMN2ALDH1A1
SCHEMBL22691739 0.60 MAPT (0.40) KDM4ENPC1RAB9ASMN1; SMN2ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1871776-A2 FUSED THIENO[2,3-B]PYRIDINE AND THIAZOLO[5,4-B]PYRIDINE COMPOUNDS FOR INHIBITING KSP KINESIN ACTIVITY SCHERING CORPORATION (US) 2008-01-02 EP disclosed
US-20060247320-A1 Compounds for inhibiting KSP kinesin activity SCHERING CORPORATION 2006-11-02 US disclosed
WO-2006098961-A2 FUSED THIENO [2, 3-B] PYRIDINE AND THIAZOLO [5, 4-B] PYRIDINE COMPOUNDS FOR INHIBITING KSP KINESIN ACTIVITY SCHERING CORPORATION (US) 2006-09-21 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060247320-A1 Compounds for inhibiting KSP kinesin activity KIFC1, KIF5B, KIF2C HSP90AB1 656/4885DAPK3 1940/4885CSNK1A1 438/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.